Nalpropion patent expiration

1. Contrave patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11278544 NALPROPION Compositions for affecting weight loss
Apr, 2024

(2 months ago)

US8815889 NALPROPION Compositions and methods for increasing insulin sensitivity
Jul, 2024

(a day from now)

US7462626 NALPROPION Compositions for affecting weight loss
Jul, 2024

(a day from now)

US7375111 NALPROPION Compositions for affecting weight loss
Mar, 2025

(8 months from now)

US9107837 NALPROPION Sustained release formulation of naltrexone
Jun, 2027

(2 years from now)

US8318788 NALPROPION Layered pharmaceutical formulations
Nov, 2027

(3 years from now)

US9125868 NALPROPION Methods for administering weight loss medications
Nov, 2027

(3 years from now)

US8722085 NALPROPION Methods for administering weight loss medications
Nov, 2027

(3 years from now)

US10307376 NALPROPION Methods for administering weight loss medications
Nov, 2027

(3 years from now)

US8088786 NALPROPION Layered pharmaceutical formulations
Feb, 2029

(4 years from now)

US11324741 NALPROPION Methods for treating visceral fat conditions
May, 2029

(4 years from now)

US8916195 NALPROPION Sustained release formulation of naltrexone
Feb, 2030

(5 years from now)

US11033543 NALPROPION Methods of providing weight loss therapy in patients with major depression
Jan, 2031

(6 years from now)

US9248123 NALPROPION Methods of providing weight loss therapy in patients with major depression
Jan, 2032

(7 years from now)

US10403170 NALPROPION Methods of treating overweight and obesity
Jun, 2033

(8 years from now)

US11139056 NALPROPION Methods of treating overweight and obesity
Jun, 2033

(8 years from now)

US9633575 NALPROPION Methods of treating overweight and obesity
Jun, 2033

(8 years from now)

US10231964 NALPROPION Compositions and methods for weight loss in at risk patient populations
Jul, 2034

(9 years from now)

US10828294 NALPROPION Compositions and methods for weight loss in at risk patient populations
Jul, 2034

(9 years from now)

US10835527 NALPROPION Compositions and methods for reducing major adverse cardiovascular events
Jul, 2034

(9 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Sep 10, 2017

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 10 September, 2014

Treatment: For chronic weight management for treating overweight or obesity; For effect on blood glucose parameters in patients with insulin resistance; Use of naltrexone and bupropion in extended-release form f...

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of CONTRAVE before it's drug patent expiration?
More Information on Dosage

CONTRAVE family patents

Family Patents